Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionAssenagon Asset Management S.A.
Latest Disclosed Ownership91,478 shares
Latest Disclosed Value $ 12,051,312
Assenagon Asset Management S.A. reports 14.33% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On April 20, 2026 - Assenagon Asset Management S.A. filed a 13F-HR form disclosing ownership of 91,478 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $12,051,312 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 80,012 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 14.33% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-20 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 91,478 11,466 14.33 12,051 6.19 0.0183
2026-01-09 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 80,012 33,065 70.43 11,348 72.20 0.0156
2025-10-07 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 46,947 -13,280 -22.05 6,590 -12.93 0.0090
2025-07-11 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 60,227 -333,228 -84.69 7,570 -82.61 0.0112
2025-04-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 393,455 367,315 1,405.18 43,516 1,119.62 0.0726
2025-01-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 26,140 -3,663 -12.29 3,568 3.93 0.0058
2024-10-23 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,803 -219,621 -88.05 3,434 -90.00 0.0063
2024-07-18 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 249,424 -88,313 -26.15 34,338 -26.28 0.0764
2024-04-24 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 337,737 22,177 7.03 46,581 12.03 0.1103
2024-01-17 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 315,560 -268,979 -46.02 41,578 -36.77 0.1104
2023-11-06 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 584,539 319,564 120.60 65,761 163.18 0.2036
2023-07-25 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 264,975 174,467 192.76 24,987 172.75 0.0864
2023-04-18 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 90,508 -117,923 -56.58 9,161 38,070.83 0.0325
2023-01-12 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 208,431 123,613 145.74 25 -99.73 0.0898
2022-10-27 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 84,818 -54,653 -39.19 9,009 -33.74 0.0346
2022-07-27 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 139,471 125,611 906.28 13,596 946.65 0.0504
2022-04-25 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,860 -71,965 -83.85 1,299 -82.23 0.0036
2022-02-01 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 85,825 74,634 666.91 7,310 581.27 0.0212
2021-10-19 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,191 -37,878 -77.19 1,073 -77.53 0.0034
2021-07-15 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 49,069 45,836 1,417.75 4,775 1,420.70 0.0162
2021-04-26 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,233 3,233 314 0.0013
2020-10-07 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -22,926 -100.00 0 -100.00
2020-07-21 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,926 22,926 2,797 0.0179
2020-01-17 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -24,885 -100.00 0 -100.00
2019-10-16 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 24,885 24,885 2,242 0.0150
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.